- Home
- IONS
as 05-09-2025 4:00pm EST
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
| Founded: | 1989 | Country: | United States |
| Employees: | N/A | City: | CARLSBAD |
| Market Cap: | 4.6B | IPO Year: | 1991 |
| Target Price: | $57.41 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Buy | Number of Analysts: | 18 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $23.95 - $52.34 | Next Earning Date: | 04-30-2025 |
| Revenue: | $717,253,000 | Revenue Growth: | -7.64% |
| Revenue Growth (this year): | -4.18% | Revenue Growth (next year): | 27.39% |
Stock Insider Trading Activity of Ionis Pharmaceuticals Inc. (IONS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hayden Michael R | IONS | Director | May 1 '25 | Buy | $31.86 | 15,000 | $477,900.00 | 50,219 | |
| Baroldi Joseph | IONS | EVP, Chief Business Officer | Apr 15 '25 | Sell | $28.40 | 3,928 | $111,555.20 | 31,926 | |
| Birchler Brian | IONS | EVP, Corp and Development Ops | Apr 15 '25 | Sell | $28.37 | 680 | $19,291.60 | 56,660 | |
| Monia Brett P | IONS | Chief Executive Officer | Mar 11 '25 | Sell | $32.32 | 140 | $4,524.80 | 180,980 | |
| O'NEIL PATRICK R. | IONS | EVP CLO & General Counsel | Feb 20 '25 | Sell | $32.35 | 1,207 | $39,046.45 | 56,245 |
Latest Ionis Pharmaceuticals Inc. News
IONS Breaking Stock News: Dive into IONS Ticker-Specific Updates for Smart Investing
Business Wire
3 days ago
Ionis to host 2025 virtual Annual Meeting of Stockholders
Argus Research
4 days ago
Daily – Vickers Top Buyers & Sellers for 05/05/2025
Simply Wall St.
4 days ago
Analysts Just Made A Sizeable Upgrade To Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Forecasts
Simply Wall St.
7 days ago
Ionis Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations
Morningstar Research
8 days ago
Analyst Report: Ionis Pharmaceuticals, Inc.
MT Newswires
8 days ago
Ionis Pharmaceuticals Lifts Revenue Forecast After Strong Q1, Oppenheimer Says
Zacks
8 days ago
Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View
GuruFocus.com
9 days ago
Ionis Pharmaceuticals Inc (IONS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...
Compare IONS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IONS Ionis Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.